Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

Engelberts PJ, Breij ECW, Valerius T, Schuurman J, Parren PWHI, Beurskens FJ.

J Immunol. 2018 Apr 15;200(8):2517. doi: 10.4049/jimmunol.1800233. No abstract available.

PMID:
29632251
2.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI.

Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15.

PMID:
29334371
3.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.

J Immunol. 2016 Dec 15;197(12):4829-4837. Epub 2016 Nov 2.

4.

Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.

de Goeij BE, Vink T, Ten Napel H, Breij EC, Satijn D, Wubbolts R, Miao D, Parren PW.

Mol Cancer Ther. 2016 Nov;15(11):2688-2697. Epub 2016 Aug 24.

5.

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ, Golay J.

Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.

6.

An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.

Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, Miller VB, Houtkamp M, Bleeker WK, Satijn D, Parren PW.

Cancer Res. 2014 Feb 15;74(4):1214-26. doi: 10.1158/0008-5472.CAN-13-2440. Epub 2013 Dec 26.

7.

Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.

Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.

8.

Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis.

Vogt MH, Teunissen CE, Iacobaeus E, Heijnen DA, Breij EC, Olsson T, Brundin L, Killestein J, Dijkstra CD.

J Neurol Neurosurg Psychiatry. 2009 Oct;80(10):1110-5. doi: 10.1136/jnnp.2008.146357. Epub 2008 Oct 17.

PMID:
18931010
9.

Surfactant protein D/anti-Fc receptor bifunctional proteins as a tool to enhance host defence.

Breij EC, Batenburg JJ.

Expert Opin Biol Ther. 2008 Apr;8(4):409-19. doi: 10.1517/14712598.8.4.409 . Review.

PMID:
18352846
10.

Homogeneity of active demyelinating lesions in established multiple sclerosis.

Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, Dijkstra CD, van der Valk P, Bö L.

Ann Neurol. 2008 Jan;63(1):16-25. doi: 10.1002/ana.21311.

PMID:
18232012
11.

Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients.

Breij EC, Heijnen P, van der Goes A, Teunissen CE, Polman CH, Dijkstra CD.

J Neuroimmunol. 2006 Jul;176(1-2):106-14. Epub 2006 May 18.

PMID:
16712958
12.

The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE.

Breij EC, Heijnen P, Vloet R, Saito T, van de Winkel JG, Dijkstra CD, Amor S, Verbeek S.

J Neuropathol Exp Neurol. 2005 Apr;64(4):304-11.

PMID:
15835266
13.

Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice.

Smith PA, Heijmans N, Ouwerling B, Breij EC, Evans N, van Noort JM, Plomp AC, Delarasse C, 't Hart B, Pham-Dinh D, Amor S.

Eur J Immunol. 2005 Apr;35(4):1311-9.

14.

The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions.

Brink BP, Veerhuis R, Breij EC, van der Valk P, Dijkstra CD, Bö L.

J Neuropathol Exp Neurol. 2005 Feb;64(2):147-55.

PMID:
15751229
15.

No association of Fc gamma RIIa, Fc gamma RIIIa and Fc gamma RIIIb polymorphisms with MS.

Breij EC, van der Pol WL, van Winsen L, Jansen MD, Dijkstra CD, van de Winkel JG, Uitdehaag BM.

J Neuroimmunol. 2003 Jul;140(1-2):210-5.

PMID:
12864991
16.

Interactions between major histocompatibility complex class II surface expression and HIV: implications for pathogenesis.

Kamp W, Breij EC, Nottet HS, Berk MB.

Eur J Clin Invest. 2001 Nov;31(11):984-91. Review.

PMID:
11737241
17.

Interactions between HIV-infected monocyte-derived macrophages and human brain microvascular endothelial cells result in increased expression of CC chemokines.

Boven LA, Middel J, Breij EC, Schotte D, Verhoef J, Soderland C, Nottet HS.

J Neurovirol. 2000 Oct;6(5):382-9.

PMID:
11031691
18.

Spatial structure, contrast polarity and motion integration.

van der Smagt MJ, Breij EC, van de Grind WA.

Vision Res. 2000;40(15):2037-45.

Supplemental Content

Loading ...
Support Center